FDA OKs Emergent’s mPox Vaccine
The Dermatology Digest
AUGUST 30, 2024
The FDA approval of ACAM2000 for immunization against mpox in high-risk individuals further strengthens and broadens our industry-leading smallpox portfolio, which includes VIGIV and TEMBEXA,” says Joe Papa, president and CEO of Emergent, in a news release.
Let's personalize your content